Background: Changes in relation to drug treatment to various control targets for diabetes were
Introduction
Type 2 diabetes affects more than 1 in 10 of the US population according to a recent report (1) , and imposes a huge burden on healthcare expenses. Previous findings from the United States National Health and Nutrition Examination Survey (NHANES) showed that the prevalence of diagnosed diabetes increased significantly from 1999 to 2006 (2) . Good control of glycemic and blood pressure targets is important in the management of type 2 diabetes. Good control of blood glucose and blood pressure reduces microvascular and macrovascular complications (3) (4) (5) .
Our previous reports have evaluated the prevalence and therapeutic target achievement in the US adults using data from the NHANES studies (2, 6) . A recent study has also shown that about 33-48% of subjects with diabetes did not meet the targets for glycemic, blood pressure or LDL cholesterol control in US NHANES 1999-2010 (7) . Better utilization of medications might improve the control of these targets. In US, eleven unique types of drugs have been approved to treat type 2 diabetes, and 9 of them have become available since 1995 (8) . New pharmacotherapies have become available, ranging from established agents to new drugs acting on the incretin pathway (9) .
Therefore it is necessary for clinicians to have a rational approach for the choice of therapy.
Although we previously investigated the achievement of glycemic, blood pressure and low-density lipoprotein (LDL) targets in NHANES 1999-2006 (2), utilization of medications in people with diabetes has not been updated. The present study provides an update on the utilization of prescribed medications for lowering blood glucose, lipids and blood pressure from 1999 to 2010.
Methods

Study design and subjects
NHANES was conducted by the National Center of Health Statistics, Centers for Disease Control and Prevention, with a stratified, multistage probability sampling design (10). Written informed consent was obtained from all participants. In NHANES 1999-2010, there were 30,752 subjects aged ≥20 years who were both interviewed and examined in the mobile examination center. After excluding all pregnant women and subjects with missing data, 28,774 subjects were included in the analysis. Among them, 3,168 subjects had self-reported diagnosis of diabetes. Subjects who answered "yes" to the interview question "Other than during pregnancy, have you ever been told by a doctor or health professional that you have diabetes or sugar diabetes?" were categorized as having diagnosed diabetes. In NHANES, diabetes was not classified into type 1 or 2, therefore 74 participants with diabetes diagnosed at age < 30 years and treated with insulin alone were further excluded in the analysis as they were considered as having type 1 diabetes (2, 11) . Therefore, a total of 3,094 subjects were included in this analysis.
Type of treatment and prescription medications
The use of prescription medications for lowering blood lipids, glucose, and blood pressure in the past month was assessed by questionnaires. Participants were asked whether they had taken or used any prescription medicine in the past month and showed the interviewer the medication containers and the exact name of all the products. If the container was unavailable, the interviewer asked the participants to verbally report this information. Details on the classification of the prescription medications have been described as previously (12, 13) . A participant, who took two or more different classes of medications for the same therapeutic use (lowering either blood lipids, glucose, or blood pressure), either as a single combination pill or several different pills, was defined as receiving polytherapy. Participants with diagnosed diabetes who were not on medication (insulin or an oral anti-diabetic drug) were assumed to have non-pharmacologic therapy (diet and lifestyle changes).
Other variables of interest
Information on race/ethnicity, education, history of cardiovascular diseases, smoking, alcohol consumption, family history of diabetes and age of diabetes diagnosis was obtained from self-reported questionnaires at baseline (2, 10, (12) (13) (14) (15) . Ever smokers were defined as subjects who had smoked ≥100 cigarettes in their lives. Regular alcohol drinking was defined as consumption of any type of alcoholic beverage at least once a week in the past year. Details on the laboratory measurement methods of other biochemical variables have been described as previously (2, 6, (11) (12) (13) (14) (15) . Microalbuminuria was defined as a urinary albumin-to-creatinine ratio ≥30 μg/mg (16) .
Triglyceride levels were log-transformed before analysis
Treatment goals for diagnosed diabetes
The definitions of different treatment goals for diagnosed diabetes were based on the recent American Diabetes Association (ADA) guidelines (16) . Patients with diabetes should be treated with the glycemic, blood pressure, and lipid targets being HbA 1c <7.0%, blood pressure <140/80 mmHg, and LDL cholesterol <100 mg/dL. We also examined the secondary lipid targets, i.e. triglycerides <150 mg/dL, and HDL cholesterol >40 mg/dL in men and >50 mg/dL in women in a separate analysis.
Statistical analysis
Data analysis was performed using the complex sampling function of SPSS version 20.0 (SPSS Inc, Chicago, IL). Variables with skewed distribution were log-transformed before analysis.
Examination sampling weights were used in all analyses to obtain estimates representative of the United States Census civilian non-institutionalized population (17) . Separate fasting sampling weights were used for the analysis involving serum triglycerides and LDL cholesterol as they were measured only in subjects who were examined in the morning session and had fasted for 8-24 hours, To obtain more reliable estimates, data from two survey cycles were combined together to produce estimates for each four-year period. To analyze the trends over time, multiple logistic or linear regression models were used, in which survey year (1999-2002, 2003-2006 and 2007-2010 ) was included as an independent continuous variable. A two-tailed P<0.05 was considered statistically significant. Increased usage of anti-hypertensive medications such as angiotensin-converting enzyme inhibitor (ACEI), aldosterone receptor antagonist (ARB), beta-blockers and diuretics was observed (P≤0.001) ( Table 3 ). The ADA guideline recommends the use of either ARB or ACEI to treat subjects with both hypertension and diabetes (11) . There was a significant increase in proportion of people taking either ARB or ACEI who could achieve blood pressure control (P=0.009) (Figure 1b ).
Results
Significant improvement could also be seen in people taking β-blockers and people taking diuretics (P<0.05). Overall by 2007-2010 60% of subjects with any anti-hypertensive drug treatment could achieve the blood pressure target (<140/80 mmHg).
Among different lipid lowering medications, statin remained the most common type of drugs across the 12-year period, and the proportions of subjects on statins increased significantly from 28.5% to 52.1% (P<0.001) ( Table 4 The proportions of people achieving other lipid targets are shown in Supplementary Table S2 .
There was no significant trend in percentages of people achieving HDL cholesterol target level, while the proportions of people achieving triglycerides target level increased significantly from 45.8% to 57.5% from 1999-2010 (P=0.023).
Discussion
The prevalence of diabetes has increased dramatically in the U.S. in the last two decades (18) .
In 2010, about 21 million adult Americans had diagnosed diabetes. Fortunately, recent evidence suggested that diabetes-related complications, such as heart attacks, have declined substantially in the U.S. (19) . Improved control of cardiovascular risk factors might have contributed to the decrease in myocardial infarction. Our study generates information on the recent trend of usage of different diabetic medications using large and nationally representative multi-stage surveys.
Favorable trends in controlling glycemia, blood pressure and dyslipidemia might reflect better utilization of medications, however from our data greater prevalence of obesity and decreased 8 prevalence of family history of diabetes were observed in the populations from 1999-2010, and these changes should not be neglected as they may also have impact on various risk factors control as well. Despite the significant increase in the use of glucose, blood pressure and lipid lowering drugs from 1999-2010, about a quarter of the participants achieved all the control targets for diabetes. Therefore efforts should be made to look for better treatment and control of diabetes.
Although by 2010 more than 80% of diabetes patients have been on glucose lowering medications, merely half of them showed good glycemic control (Table 2 and Figure 1a ). This suggests that there is still improvement to be made in order to enhance the efficacy of the use of anti-diabetic drugs. Since 2003, metformin has become the most commonly used glucose lowering drug. It is the recommended first line therapy because of its effectiveness in weight reduction, low cost and low risk for hypoglycemia (9) . Studies also showed reduction in cardiovascular and all-cause mortality and reduction in cancer risks with metformin use (20) . The use of DPP-4 inhibitors was first observed in 2007. In our sample population about 33% of participants taking the drug could achieve glycemic control, which was less than those taking other medications like metformin. This agrees with previous finding that DPP-4 inhibitors could improve
HbA1 c level to a lesser extent than metformin (23). The drug is not widely used for several considerations. These agents are not more effective in glucose lowering than other prevalent medications; there are also reservations of long-term safety of these agents; these agents are expensive and result in greater prescription costs than sulfonylurea and metformin (8) . Despite the above reservations on DPP-4 inhibitors, a potential advantage of these types of drug is their relatively fewer adverse effects. Compared to sulphonylureas, they cause less hypoglycemia and weight gain (24). Such advantage makes this drug attractive to the elderly, especially for those with co-morbidities that prevent the use of other medications.
Overall more than half of the participants could achieve blood pressure control from 1999-2010, and the percentage has been significantly increasing across the period. Also, about 60% of subjects taking various anti-hypertensive medications could generally achieve the control targets.
Considering the various anti-hypertensive medications, there was increasing utilization of ARB, diuretics and beta-blockers. In particular, the percentage of subjects using beta-blockers and ARB doubled and tripled respectively from 1999-2010. Diuretics and beta-blockers are the traditional classes of anti-hypertensive agents. However there has been controversy over the adverse effects of these traditional drugs on glucose homeostasis. Beta-blockers and diuretics are generally regarded as agents that can increase the risk of new onset diabetes (25). Therefore it has been argued that those at risk of developing diabetes should avoid taking beta-blockers and diuretics, though there is a debate on the clinical significance of new onset diabetes associated with these drugs (26). The increasing use of diuretics and beta-blockers in this study is probably due to the fact that diuretics are more commonly used by the elderly while beta-blockers are used to treat hypertensive patients with angina. Nevertheless, regular monitoring should be considered to manage the metabolic adverse effects at an early stage while maintaining good blood pressure control (27).
Statins have been increasingly prescribed in 1999-2010 and more than half of the participants were on this class of drugs. Our data shows that there was significant improvement in LDL cholesterol control, probably due to the effects of statins and a decline in hypertriglyceridemia.
There have been discussions on whether statins confer more benefits in diabetic patients, and their effects on glycemic control (28, 29). The trend in the use of statins to lower lipid levels is promising, while the effect of statins on glycemic control in diabetic patients remains controversial (30).
However, considering their efficacy in reducing cardiovascular events, stains will remain as one common drug class to treat dyslipidemia.
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